Affymetrix: Price Always Matters

When I wrote about Affymetrix (Nasdaq: AFFX  ) a year ago and suggested that the stock was too expensive and that the company had more competition than some people might realize, you would have thought I'd shot the Easter Bunny and made it into hasenpfeffer. Since then, the stock has gotten chopped down by more than half and sales have been hurt by competitors. Huh, I guess price and competition may just matter after all.

This quarter didn't offer up much in the way of good news, either. Overall revenue dropped 5%, product revenue fell 6%, and the company once again missed guidance on the bottom line. As you might imagine with this sort of company (a razor/razor blade business model with significant operating leverage), margins were weak beneath the lower sales performance.

Speaking of competition, management cited that as a primary issue this quarter. When you look around the sector and see how well rival Illumina (Nasdaq: ILMN  ) did this quarter (within 10% of a 52-week high), you see part of the problem. In response, the company announced that it's cutting the price of the 500k GeneChip to about $250. That'll hurt margins in the short run, but it should help preserve marketshare ahead of the launch of a next-gen system that should help get revenue growth going again.

Affymetrix is still a leader in gene expression technology, but this market is getting more like regular ol' diagnostics. That's not terrible -- companies like Beckman Coulter (NYSE: BEC  ) , Roche, and Invitrogen (Nasdaq: IVGN  ) have built good businesses -- but it does speak to the "it's different this time" syndrome that has been an issue with this company in the past. There is plenty of money left to be made from genomics and proteomics, but the rest of the industry is not going to just cede it all to Affymetrix.

Despite all of that, I'm more interested in this stock now than I have been in quite a while. I get very skeptical of technology leaders when investors begin assuming "it's different this time" and push the stocks up to unrealistic levels. But I get very interested when those same investors get disillusioned and bail out. It's not uncommon for the misevaluation to swing completely the other way and a company with legitimate technology and competitive products to be treated as though it's out of the running. While I would expect the going to be tough for Affymetrix for a little while yet, opportunistic investors should keep an eye on this one.

For more related Foolishness:

Affymetrix isa recommendation ofMotley Fool Rule Breakers, the newsletter service that tracks companies shaking things up. If you'd like to see what other innovators David Gardner has recommended, try out Rule Breakers free for 30 days.

Fool contributorStephen Simpsonhas no financial interest in any stocks mentioned (that means he's neither long nor short the shares).

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 515215, ~/Articles/ArticleHandler.aspx, 10/23/2016 12:40:59 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

3/31/2016 4:00 PM
AFFX.DL $14.01 Down +0.00 +0.00%
Affymetrix CAPS Rating: **
BEC.DL22 $0.00 Down +0.00 +0.00%
Beckman Coulter, I… CAPS Rating: *****
ILMN $141.80 Down -1.03 -0.72%
Illumina CAPS Rating: *****
IVGN $22.23 Down +0.00 +0.00%
Invitrogen CAPS Rating: ****